Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Chris Murphy, Chief Financial and Business Officer, will engage in a fireside chat on December 4, 2024, at 9:35 a.m. The company, which focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide a live audio webcast accessible through their website's Investors & Media section. The replay will remain available for 90 days after the event.
Details
News Market Reaction – THRD
The recorded move for THRD in the trading session of this news was +3.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.